Dec 29 (Reuters) - Pfizer:
* Discontinues a phase 3 trial of figitumumab in non-small cell lung cancer
(nsclc) for futility
* Says addition of figitumumab to paclitaxel plus carboplatin would be unlikely
to meet the primary endpoint
* Says discontinuation follows a halt in new patient enrollment to a4021016 in
September 2009
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Discontinues a phase 3 trial of figitumumab in non-small cell lung cancer
(nsclc) for futility
* Says addition of figitumumab to paclitaxel plus carboplatin would be unlikely
to meet the primary endpoint
* Says discontinuation follows a halt in new patient enrollment to a4021016 in
September 2009
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.